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Introduction: Despite progress made in child survival in the past 20 years, 5.9 million children under five
years died in 2015, with 9% of these deaths due to diarrhea. Rotavirus is responsible for more than a third
of diarrhea deaths. In 2013, rotavirus was estimated to cause 215,000 deaths among children under five
years, including 89,000 in Asia. As of April 2017, 92 countries worldwide have introduced rotavirus vac-
cination in their national immunization program. Afghanistan has applied for Gavi support to introduce
rotavirus vaccination nationally. This study estimates the potential impact and cost-effectiveness of a
national rotavirus immunization program in Afghanistan.
Methods: This study examined the use of Rotarix (RV1) administered using a two-dose schedule at 6 and
10 weeks of age. We used the ProVac Initiative’s UNIVAC model (version 1.2.09) to evaluate the impact
and cost-effectiveness of a rotavirus vaccine program compared with no vaccine over ten birth cohorts
from 2017 to 2026 with a 3% annual discount rate. All monetary units are adjusted to 2017 US$.
Results: Rotavirus vaccination in Afghanistan has the potential to avert more than one million cases;
660,000 outpatient visits; approximately 50,000 hospital admissions; 650,000 DALYs; and 12,000 deaths,
over 10 years. Not accounting for any Gavi subsidy, rotavirus vaccination can avert DALYs at US$82/DALY
from the government perspective and US$80/DALY from the societal perspective. With Gavi support,
DALYs can be averted at US$29/DALY and US$31/DALY from the societal and government perspective,
respectively. The average yearly cost of a rotavirus vaccination program would represent 2.8% of the total
immunization budget expected in 2017 and 0.1% of total health expenditure.
Conclusion: The introduction of rotavirus vaccination would be highly cost-effective in Afghanistan, and
even more so with a Gavi subsidy.
 2017 Elsevier Ltd. All rights reserved.
1. Introduction
Despite a 53% reduction in the rate of all-cause mortality world-
wide since 1990, 5.9 million children under five years died in 2015,
with 9% of these deaths due to diarrhea [1]. In the most recent
Global Burden of Disease (GBD) 2015 study, diarrheal diseases
were the fourth leading cause of death among children under five
years, responsible for 499,000 deaths, representing 8.6% of all
deaths in this age group [2]. Rotavirus is responsible for more than
a third of these deaths [2]. In 2013, the World Health Organization
(WHO) and Centers for Disease Control and Prevention (CDC) esti-
mated 215,000 deaths among children under five years, including
89,000 in Asia [3]. Rotavirus infects nearly every child by age 5
and is the leading cause of severe, dehydrating diarrhea in most
low-income countries in Asia and Africa [4].
The GBD 2015 study estimated 103,692 child deaths due to
diarrhea in the Eastern Mediterranean Region (EMR) and 13,180
deaths due to rotavirus [5,6]. The Afghanistan Demographic and
Health Survey (DHS) 2015 reported that 29% of children under five
years had diarrhea in the two weeks before the survey [7]. Surveil-
lance data reported that more than 45% of all hospitalizations for
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gastroenteritis in the same population in the country are attributa-
ble to rotavirus [8]. In addition, Afghanistan is one of the ten coun-
tries that account for almost two thirds of all rotavirus deaths in
2013 [3]. All of this evidence points to significant rotavirus burden
in Afghanistan and the region.
There are currently two WHO prequalified live oral attenuated
vaccines available to countries to help abate the burden of rota-
virus disease. These vaccines are the monovalent (RV1) Rotarix
(GlaxoSmithKline Biologicals, Rixensart, Belgium) and the pentava-
lent (RV5) RotaTeq (Merck & Co. Inc., West Point, PA, USA) [9].
Gavi, the Vaccine Alliance, provides donor support to help eligible
countries introduce these vaccines into their national immuniza-
tion programs [10]. As of April 2017, 92 countries worldwide have
introduced rotavirus vaccine in their national immunization pro-
gram. Afghanistan introduced Hib vaccines in 2009, pneumococcal
conjugated vaccines (PCV) in 2013 and inactivated polio vaccine
(IPV) in 2015 [11]. Discussions around introducing rotavirus vacci-
nes have been ongoing for several years and the country decided to
apply for support from Gavi in 2017. Gavi has approved Afghani-
stan’s application and rotavirus vaccine introduction is planned
for the first quarter of 2018.
This study evaluates the projected impact and cost-
effectiveness of a national rotavirus vaccine introduction in Afgha-
nistan and provides estimates of its cost. The aim is to help policy
makers and programmanagers make informed decisions about the
allocation of health resources in Afghanistan.
2. Materials and methods
This study examined the use of Rotarix (RV1), which would be
administered following a two-dose schedule at 6 and 10 weeks of
age alongside Penta1 and Penta2, respectively. We evaluated the
impact and cost-effectiveness of a rotavirus vaccine program com-
pared with no vaccine, at the national level, over ten birth cohorts
starting in 2017. Rotavirus disease events and treatment costs are
estimated over the first 5 years of life. The estimated average life
expectancy of each birth cohort is used to estimate healthy future
years of life gained. Future health benefits and costs are discounted
using a 3% annual rate. We examine results from the government
and societal perspectives. All monetary units were adjusted to
2017 US$.
The primary outcome measure of the analysis is the discounted
cost per disability adjusted life year (DALY) averted. Other out-
comes include the incremental cost of the vaccine program, as well
as the number of averted cases, visits, hospitalizations, treatment
costs, and deaths.
2.1. Model
We used UNIVAC (version 1.2.09), a model developed at the
London School of Hygiene and Tropical Medicine which builds on
previous tools collaboratively developed by the Pan American
Health Organization’s (PAHO) ProVac Initiative, GAVI’s Hib Initia-
tive, PATH, and the CDC [12]. UNIVAC is a single universal vaccine
impact and cost-effectiveness decision support model developed in
a standardized, accessible Excel-based interface (Excel, Microsoft
Corp, Redmond, WA, US). This model is being used for the first time
in Afghanistan to evaluate the impact and cost-effectiveness of
rotavirus vaccination. UNIVAC’s precursor, TRIVAC, has been used
in many studies worldwide and shares many similarities with UNI-
VAC [13]. In brief, UNIVAC is a deterministic static cohort model
that can be used to generate transparent and conservative esti-
mates of the projected impact of new vaccines. It has been pur-
posefully designed for use in low- and middle-income countries,
by national teams working in conjunction with the Ministry of
Health. Model input parameters include demographics, burden of
disease, vaccine schedule, vaccine efficacy, vaccine coverage, vac-
cine timeliness, vaccine program costs, and health service costs.
Input parameters were gathered from the literature and local
sources and then discussed by a group of local experts convened
specifically to participate in the cost-effectiveness analysis by pro-
viding insight and validating the main assumptions used. This
group was comprised of experts from the directorate general of
preventive medicine, the health economics and financing depart-
ment (HEFD), the national expanded program on immunization
(EPI), and the health management and information system (HMIS)
unit of the Afghan Ministry of Public Health (MoPH).
2.2. Disease burden
2.2.1. Incidence and severity
We estimated the incidence of rotavirus disease cases in chil-
dren under five years to be approximately 10,000 per 100,000
per year, based on a global systematic review and meta-analysis
study by Bilcke et al. [14]. This incidence level is consistent with
the incidence observed by Zaman et al., in the placebo arm of the
RotaTeq randomized controlled trial in Bangladesh and Vietnam
[15]. We assumed that 17.25% of the rotavirus disease cases would
be severe based on the mean proportion reported for Bangladesh,
India, Nepal, and Pakistan in the Platts-Mills MAL-ED study [16].
We therefore assumed 1725 severe rotavirus disease cases per
100,000 per year, and 8275 non-severe rotavirus disease cases
per 100,000 per year, in children under five years. The Afghanistan
Demographic and Health Survey (DHS) 2015 reported that 54.2% of
children with diarrhea were taken to a medical health facility or
healthcare provider for advice or treatment [7]. We therefore
assumed that 935 severe cases and 4485 non-severe cases would
visit a healthcare facility for outpatient treatment, per 100,000
per year in children under five years. In addition, the number of
severe rotavirus disease cases resulting in an inpatient visit was
estimated from routine HMIS data to be 403 per 100,000 per year
in children under five years, implying an overall treatment seeking
rate of nearly eighty percent for severe cases [17]. Estimated
weighted DALYs for moderate and severe diarrhea in 2013 were
0.188 and 0.247, respectively [18]. When calculating DALYs, we
assumed the average duration of rotavirus disease to be 7 days
for severe cases and 3 days for non-severe cases [19].
2.2.2. Mortality
There are no robust data on mortality attributed to rotavirus in
Afghanistan. We used a rotavirus disease mortality rate of 98
deaths per 100,000 per year in children under five years, as esti-
mated by Tate et al. [3]. To account for uncertainty, we also looked
at a high mortality scenario (applying a 15% increase to this mor-
tality rate) as well as a scenario accounting for a rotavirus mortal-
ity rate as low as 27.83 deaths per 100,000 per year in children
under five years, as reported by Institute for Health Metrics and
Evaluation (IHME) in GBD 2015 [20].
2.3. Vaccine coverage and efficacy
Because Afghanistan anticipates delivery of rotavirus vaccine
alongside Pentavalent vaccine, we used coverage data from Penta
(77.3%) reported from the national immunization coverage survey
2013 [21] to project expected coverage rates of the rotavirus vac-
cination program. Because DHS data from 2015 reports a lower
coverage rate of Penta, in an alternative scenario, we also looked
at a different coverage projection, using a lower initial rate [7].
Coverage projections are in line with the MoPH strategy to reach
90% immunization coverage of dose one for all antigens nationally
by 2020 [22,23]. We assumed that timeliness of the first two doses
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of rotavirus vaccine would be similar to the timeliness observed for
Penta1 and Penta2 [21]. Based on recommendations of the WHO
SAGE, we did not apply the age restriction to vaccination schedule
in this analysis [9].
Vaccine efficacy for severe and non-severe cases in the first year
following vaccination was estimated based on findings of a ran-
domized, double blind, placebo-controlled trial study of Rotateq
vaccination conducted in Bangladesh in 2010. We assumed vaccine
efficacy for the two-dose schedule to be 53.1% and a single dose
was conservatively assumed to provide half that efficacy [15,24].
We assumed rates of waning vaccine-induced protection consis-
tent with the waning observed in the trial. We conservatively
excluded any indirect benefits of vaccination such as herd effects.
Input parameters and sources of data used for estimating disease
burden are shown in Table 1.
2.4. Vaccine price and delivery cost
In the base case scenario, we used the last known vaccine price
secured by Gavi of US$2.02 per dose [25]. We assumed vaccine
price would remain constant at US$2.02 over 10 years (2017–
2026) [26]. Based on the Gavi eligibility and transition policy,
Afghanistan falls in the initial self-financing transition phase where
the minimum co-financing required is US$0.20 per dose with no
annual increase as we do not anticipate Afghanistan’s co-
financing share to change during the period of analysis [23,27].
We applied this co-financing amount per dose in alternative
scenarios.
We used a wastage rate of 8% as reported for PCV [28], a proxy
for rotavirus vaccine wastage, and applied 5% and 7% of the vaccine
price to account for international handling and delivery, respec-
tively [23]. We accounted for US$0.80 as a unit cost for safety bags
which have a capacity of 100 doses [23].
To account for additional (incremental) costs of delivering the
vaccine, we used cMYP data for the year 2017 and estimated
the share (US$1.06) that would be incremental for the delivery of
the rotavirus vaccine. This amount reflects the average cost per dose
of vaccines delivered by the routine immunization program
accounting for cost of personnel, transportation, cold chain, other
capital equipment and other routine recurrent costs. While we
use the average cost per dose delivered for this calculation, we
believe the average cost for these categories is representative of
the incremental cost of adding a new vaccine. We also explored a
higher, doubled incremental delivery cost in an alternative scenario.
2.5. Health service costs
The costing of the Basic Package of Health Services (BPHS)
assessment in Afghanistan in 2016 estimated a cost of US$1.70
per health facility visit for a diarrhea episode [29]. Similarly, the
facility cost of an inpatient case was estimated to be US$8.80. To
estimate household costs, we used secondary data from a publica-
tion by Rheingans et al. [30], using the household costs associated
with childhood diarrhea for Bangladesh as a proxy for those in
Afghanistan (Table 2).
2.6. Scenario analysis
In UNIVAC, base case results are calculated using our best esti-
mates of each input parameter. However, each parameter intro-
duces an additional range of uncertainty. A scenario analysis is a
way to deal with uncertainties around model parameter estimates
and assumptions. This form of uncertainty analysis helps to evalu-
ate different policy scenarios and/or ranges of parameter estimates
by creating a series of ‘what if’ scenarios. The range of results pro-
vided by comparing the base case to alternative scenarios can be a
powerful input to policy discussions, particularly where scenarios
with inputs that are unfavorable to the vaccine (e.g. low mortality,
no herd effects, no Gavi subsidy) are still shown to generate cost-
effective results.
3. Results
3.1. Base case scenario
Cost-effectiveness results are presented using the discounted
incremental cost-effectiveness ratio (ICER). This outcome is calcu-
lated by dividing the net costs of introducing rotavirus vaccine by
the incremental health benefits. ‘Incremental’ refers to the addi-
tional health benefits of introducing or implementing a new health
intervention. We compare the implementation of a rotavirus vac-
cine program to the status quo, that is, relative to no vaccination.
Table 3 presents a summary of the main study outputs, illustrating
the impact of rotavirus vaccination over ten years beginning in
2017, accounting for a vaccine price of US$2.02 per dose.
In the base case analysis, the discounted cost per DALY averted
is US$82 from the government perspective and US$80 from the
societal perspective, making rotavirus vaccination a highly cost-
effective intervention in Afghanistan relative to GDP per capita
Table 1
Input parameters and source of data for estimation of disease burden.
Parameter Estimate Reference(s)
Age-specific rates per 100,000 per year among children aged 1–59 months
Non-severe RVGE cases 8275 #14 and #16
Non-severe RVGE visits 4485 Derived from #7
Severe RVGE cases 1725 #14 and #16
Severe RVGE visits 935 Derived from#7
Severe RVGE hospitalized 403 #5 and #7
Severe RVGE deaths 98 #3
Disability weight for DALY calculations
Rotavirus (non-severe) case 0.188 #18
Rotavirus (severe) cases 0.247 #18
Mean duration of illness (in days)
Rotavirus (non-severe) case 3 #19
Rotavirus (severe) cases 7 #19
Age distribution of illness cases
Age distribution Cumulative percentage #8
<1 month 0.4%
<2 months 5.1%
<3 months 11.4%
<6 months 27.1%
<1 year 69.4%
<2 years 92.8%
<3 years 98.0%
<4 years 99.2%
<5 years 100%
Table 2
Input parameters for estimating health services costs (all costs are presented in 2017 US$).
Parameter Government cost Households costs Society cost Reference(s)
Non-severe cases (facility outpatient) 1.72 1.97 3.69 #30 and #31
Severe cases (facility outpatient) 1.72 7.08 8.80 #30 and #31
Severe cases (hospitalization) 8.80 7.14 15.94 #30 and #31
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threshold of US$562 [31]. Afghanistan does not yet have its own
cost-effectiveness threshold so we used one time per capita GDP
as the threshold.
3.1.1. Health impact
Table 4 reflects the projected discounted health benefits under
the base case scenario with and without the vaccination program.
Introduction of rotavirus vaccine in Afghanistan could result in a
reduction of more than one million cases of rotavirus, prevention
of approximately 650,000 DALYs, and would avert around 12,000
deaths by vaccinating over a 10-year period starting in 2017.
Annual reduction of rotavirus cases and deaths would average
122,000 and 1200 respectively once the program is fully
implemented.
3.1.2. Cost of care averted
Over the 10-year period, rotavirus vaccination would save the
government US$1.35 million in treatment costs. Considering the
societal perspective, accounting for household out-of-pocket costs,
vaccination would avert around US$2.80 million (Table 4).
3.1.3. Cost of vaccination program
In the base case scenario, the discounted cost of the vaccination
program represents US$55 million for the 10-year period, or US
$5.5 million per year on average. This estimate is considering that
Afghanistan would have to pay the full price of the vaccine when,
in reality, the country supports only a smaller share (the co-
financing share) of the vaccine price. Accounting only for the co-
financing amount of US$0.20 per dose and the delivery cost, the
vaccination program cost is reduced to US$22 million for the 10-
year period, or US$2.20 million per year on average. Additional
details are provided in the alternative scenarios section.
3.1.4. Alternative scenarios
We examined five alternative scenarios, four of which use the
vaccine price that Afghanistan is anticipated to pay. The range of
‘what if’ scenarios explored in the analysis cover both more and
less favorable options and were informed by discussions with local
experts (Table 5). When comparing results obtained for each alter-
native scenario to a threshold of one time GDP per capita for Afgha-
nistan in 2016 [31], all scenarios prove to be highly cost-effective
(ICER remains below US$562 GDP per capita) from the societal as
well as from the government perspective. From the government
perspective, the cost per DALY averted ranged from a minimum
of US$27 for a scenario considering a higher disease burden (sce-
nario 3) to a maximum of US$380 for our least favorable scenario,
assuming a low burden of disease, higher vaccine delivery costs
and no Gavi subsidy (scenario 6). From the societal perspective,
the cost per DALY averted ranged from a minimum of US$25 to a
maximum of US$373 for the same two scenarios (scenario 3 and
6 respectively). Fig. 1 shows the different ICERs per scenario for
both the government and the societal perspectives.
4. Discussion
This is the first formal analysis of the cost-effectiveness of rota-
virus vaccine in Afghanistan. The analysis was conducted by mem-
bers of the Afghanistan National Immunization Technical Advisory
Group and Ministry of Public Health (MoPH). All input parameters
were discussed and endorsed by a group of national and interna-
tional experts. A strength of this study is the consensus achieved
Table 3
Summary of analysis outputs.
Key model outputs Base case scenario
Without
vaccine
With
vaccine
Baseline rotavirus deaths (2017) 4880 3860
Baseline rotavirus admissions (2017) 20,069 15,874
Baseline rotavirus visits (2017) 269,898 213,479
Baseline rotavirus cases (2017) 497,999 393,897
Model outputs with vaccination over 10 years, benefits and costs discounted
Cost per DALY averted [government; society] US$82; US$80
DALYs averted 651,283
Cases averted 1.22 million
Outpatient visits averted 661,746
Inpatient visits averted 49,207
Deaths averted 11,966
Health costs averted (government) US$1.35 million
Health costs averted (societal) US$2.8 million
Vaccination program costs [with; w/o Gavi
subsidy]
US$55 million; US$22
million
Table 4
Discounted Health and economic benefits (10 cohorts vaccinated over the period of
2017–2026).
No vaccine With vaccine Averted
Health benefits
Cases 5,045,332 3,824,319 1,221,013
Non-severe 4,175,012 3,164,624 1,010,388
Severe 870,320 659,695 210,625
Visits 2,734,395 2,072,648 661,746
Non-severe 2,262,831 1,715,207 547,624
Severe 471,563 357,441 114,122
Hospitalization 203,327 154,120 49,207
Deaths 49,444 37,478 11,966
Economic benefits
Government perspective US$5,639,844 US$4,286,135 US$1,353,709
Visits US$4,085,537 US$3,104,902 US$980,635
Hospitalizations US$1,554,307 US$1,181,233 US$373,074
Societal perspective US$11,580,317 US$8,800,740 US$2,779,578
Visits US$8,764,901 US$6,661,097 US$2,103,805
Hospitalizations US$2,815,416 US$2,139,643 US$675,773
Bold represents total numbers.
Table 5
Description of alternative scenarios explored.
Scenario 1 Base case scenario –
Scenario 2 Base case accounting
for Gavi subsidy
Vaccine price lowered from US
$2.02 per dose to US$0.20 to
reflect co-financing amount paid
by the country
Scenario 3 Higher burden of
disease, Gavi subsidy
Incidence of rotavirus disease
was increased by 15% for cases,
visits, hospitalizations and deaths
Vaccine price US$0.20 per dose
Scenario 4 Lower coverage rates,
Gavi subsidy
Examining lower coverage rates
in the first four years of the
vaccination program to reflect
2015 DHS data
Vaccine price US$0.20 per dose
Scenario 5 Low burden of disease
and high vaccine
delivery costs, Gavi
subsidy
Examining a reduced burden of
disease (cases, visits, and number
of deaths based on IHME GBD
data)
Double incremental health
system cost per dose (US$2.12
instead of initial US$1.06)
Vaccine price US$0.20 per dose
Scenario 6 Low burden of disease
and high vaccine
delivery costs, No Gavi
subsidy
Examining a reduced burden of
disease (cases, visits, and number
of deaths based on IHME GBD
data)
Double incremental health
system cost per dose (US$2.12
instead of initial US$1.06)
Vaccine price US$2.02 per dose
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across several national stakeholders on the input parameters used
and scenarios evaluated. The study has also helped to increase the
capacity of the national team to conduct national economic evalu-
ations for other vaccines in the future.
Based on recommendations made by the WHO Commission for
Macroeconomics in Health [32], interventions were historically
considered cost-effective, if the cost per DALY averted was less
than three times a country’s GDP per capita, and highly cost-
effective if the cost per DALY averted was less than one time
GDP per capita. Recently WHO has updated these recommenda-
tions. Rather than using a uniform threshold based on per capita
income, WHO now recommends that countries should establish
their own specific thresholds while taking into consideration other
factors such as affordability and feasibility [33]. While this new
recommendation was discussed among the study group of experts,
given the challenges for developing an appropriate threshold for
Afghanistan, the study team decided to use one time the GDP per
capita income, which is broadly consistent with the threshold used
in Thailand [35] and far more conservative than the historical WHO
recommendation (three times GDP per capita). In the base case
scenario, excluding a Gavi subsidy, rotavirus vaccine would be
highly cost-effective in Afghanistan, both from a societal and gov-
ernment perspective, with the ICER ranging from US$80 to US$82
per DALY averted. This finding is reinforced by the alternative sce-
narios, which include a scenario with multiple key inputs unfa-
vourable to vaccination. There is limited information available
about the potential cost-effectiveness of other interventions in
Afghanistan, our estimates suggest that rotavirus vaccination
would be at least as cost-effective, if not more so, than strategies
to reduce maternal mortality [34].
Considering the support the country can receive from Gavi, the
ICER ranges from US$29 to US$31 from the societal and govern-
ment perspective, respectively. The average yearly cost of a rota-
virus vaccination program would represent 2.8% of the total
immunization cost expected in 2017 and 0.1% of the total health
expenditures [23,35].
One of the limitations of the study was the lack of high quality
local data for some of the input parameters, for example, cost of
hospital admission, rate of rotavirus mortality etc. However, we
included internationally validated estimates in the model and
tested for uncertainty around those estimates. In addition to dis-
cussions among the group of local experts, data inputs were vali-
dated by representatives of the MoPH, donors, international
technical agencies, and local civil society organizations during a
consultation workshop organized in Kabul, Afghanistan. Another
important limitation is the exclusion of potential herd effects from
the model. However, a recent effectiveness study in Bangladesh
found limited evidence for herd effects [15] and inclusion of these
benefits would only have made the case for vaccination stronger.
In summary, this analysis demonstrates that rotavirus vaccina-
tion is likely to be highly cost-effective and avert a substantial
health and economic burden of disease in Afghanistan. The avail-
able evidence demonstrates that Afghanistan currently has one of
the largest rotavirus disease burdens globally and rotavirus vacci-
nation can have an enormous impact on this burden while mini-
mally increasing the financial outlay. This study plays an
important role in justifying Afghanistan’s decision to introduce
rotavirus vaccination by demonstrating how impactful and cost-
effective this intervention will be.
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